Immuron Ltd — Regulatory Filings 2007

Jun 3, 2007

Company Announcement

Anadis signs Heads of Agreement with SPC Ardmona Ltd for health-food research and production

Monday 4 June 2007

Anadis Limited (ASX: ANX) today announced the signing of a heads of agreement with SPC Ardmona Operations Limited (SPCA), a fully-owned subsidiary of Coca-Cola Amatil Ltd (ASX: CCL).

The heads of agreement announces a research, development and commercialisation alliance between the two companies. Anadis will become an Innovation Satellite for the development and enhancement of consumer foods in the growing 'healthy food' segment.

Anadis and SPCA will work together on significant projects of definitive product advancement and differentiation for SPCA.

SPCA is Australia's largest fruit processor and is firmly committed to the innovation of healthy food-based products. The companies believe this strategy will benefit both the health of Australian consumers as well as the companies involved with the manufacture and sale of these products.

Anadis will be a unique partner for SPCA, with its expertise in research and development coupled with an ability to provide relevant underlying science, intellectual property, research management and patented nutraceutical ingredients. Anadis already has patents in the nutraceutical arena and links into senior academics in the nutrition field in Victoria.

Dr Zeil Rosenberg, CEO of Anadis Limited, said: "This heads of agreement demonstrates great confidence by SPC Ardmona, and thereby Coca-Cola Amatil, in Anadis' credentials in the growing healthcare food market. It reflects well on our scientific team to be given the opportunity to create natural health-focused foods for large consumer markets, a product of the 'wellness' revolution, focused on preventative health through, amongst others avenues, high quality nutritional foods."

SPC Ardmona Managing Director Nigel Garrard said: "For a company of our size and with our commitment to quality, we are always looking for new and innovative ways to improve our supply of foods for the healthy food market. We are confident our alliance with Anadis will assist us greatly to do this."

For further information contact:

Dr Zeil Rosenberg (US) - CEO Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Dr Grant Rawlin - Head of R&D

Email: grant.r@anadis.com.au Tel: +61 3 9358 6388

Arie Nudel - Investor Relations

Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Richard Allen - Media

Email: richard@oxygenpr.com.au Tel: +61 3 9915 6341

About Anadis Limited:

Anadis is a biotechnology company headquartered in Melbourne, Victoria and listed on the Australian Stock Exchange (ASX Symbol: ANX). The company is strongly research-based and specialises in developing fast-acting "passive" immunity solutions to a range of diseases caused by bacteria and viruses. Naturally-derived polyclonal antibodies and bioactives produced on a large scale through hyperimmunised dairy cattle are a key element of the company's extensive and proprietary technology and products.

Products include:

Travelan, which significantly decreases the risk of the medical condition known as travellers' diarrhoea and the $\bullet$ symptoms of gastrointestinal disorders caused by bacterially-contaminated food and water. Travelan has been launched and is available in several countries

EVProtec a preventative product containing antibodies against Enterovirus 71, a virus which causes epidemics of a debilitating polio-like illness, as well as hand, foot and mouth disease, in Southeast Asia. The product is in the pre launch stage.

Research programs include:

The "Ectoplasm" Program - A project in conjunction with Australian emergency response agencies developing a system for the containment and decontamination of hazardous materials.

A set of Biodefence and Respiratory Protection technologies, focused on short-term immediate protection from airborne infections such as anthrax and plague.

The Influenza Program utilising antibodies and their fragments as inhalants for the prevention and treatment $\bullet$ of influenza, including avian flu.

Bio-Shield 10 a range of "bio-shielding" technologies which shield orally administered proteins from degradation during passage through the stomach. Initially targeted for use in the probiotic market, Bio-Shield 10 is the basis of a novel oral and respiratory tract delivery system being developed for the next generation of vaccines and therapeutic proteins.

ANADIS - Antibodies against Disease

Visit our websites: www.anadis.com.au and www.travelan.com